Patients
Novel Treatments Before They're Available
Pancreatic Cancer is a very complex disease that develops as a result of reversible or irreversible damage to critical genes in a multistep process involving the accumulation of genetic and epigenetic changes. These alterations lead to losses of or abnormal function of genes affecting processes that maintain or regulate orderly normal cell function resulting in the phenotypic manifestation of specific types of the cancer. The cells that have acquired the initial gatekeeper alterations undergo localized evolution at increments to convert the tumor cells to become aggressive in their ability to proliferate as well as to invade and spread to distant sites.
What is a clinical trial?

To put it in the simplest terms a clinical trial is a research study that is done to find out if a treatment can improve a person’s health. The development of innovative medicines go through a clinical trial that takes place in 4 phases. Each of the phases involve in-human clinical trials designed to evaluate the new drug in terms of safety, dosing regimen, efficacy, and finally the eventual use in practice.

People who take part in clinical trials are volunteers. Clinical trials cannot be done without the people who choose to participate. Some of the reasons that people the one would choose to participate in a clinical trial are:

  • to take on a more active role in their own health care
  • to have better access to novel treatments before they are available to the public or
  • to aid or support others by contributing to medical research that finds new or more effective treatments for people with illnesses and diseases
Why are clinical trials performed?

Clinical trials are really the fastest and safest way to find treatments that help improve people’s health. When people participate in clinical trials they help contribute to medical research that finds new or better treatments for people with illnesses and diseases. The results of every clinical trial are important because they give researchers more information about the risks and benefits of the treatments in the trial.

Clinical Trial Information Disclosure

Research based companies are required to prove the safety and efficacy of all new medicines in clinical trials. Vitalgenics places great importance on respecting and protecting the safety of research participants. Principles for the conduct of clinical research are set forth in internationally recognized documents, such as the Declaration of Helsinki and the Guideline for Good clinical Practice of the international conference on Harmonization (icH). The principles of these and similar reference standards are translated into legal requirements through laws and regulations enforced by national authorities such as the U.S. Food and Drug administration (FDA). We remain committed, to sponsoring clinical research that fully complies with all legal and regulatory requirements.

Providing access to information about clinical research studies and their results benefits study participants, patients, healthcare providers and the wider public. This information helps people make informed decisions about potential treatment options as well as potential participation in clinical studies. Vitalgenics therefore makes every effort to comply with national and international standards for disclosure of clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments in patients.
You may contact us regarding Case Studies that are being scheduled or are currently underway at info@Vitalgenics.co

Disclaimer

This information contained on this web platform was factually accurate on the date it was published. Vitalgenics assumes no duty to update the information to reflect subsequent developments. Visitors to our site should not rely upon the information as current or accurate after its publication date. Visitors should never rely on any information contained for medical advice or used to make any decision regarding their healthcare. The information contained herein constitutes forward-looking statements relating to Vitalgenics business, including express or implied discussions regarding potential new biomedical products, potential new indications for existing products, or regarding potential future revenues from any such products. All forward-looking statements reflect the current views of Vitalgenics regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee whatsoever that any new products will be approved for sale in any geographical market, or that any new indications will be approved for existing products, or that such products will achieve any particular revenue levels.

In particular, management’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical therapies; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; Vitalgenics ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; general competition; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Vitalgenics current Private Placement Memorandum. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.